Cell-associated HIV RNA: a dynamic biomarker of viral persistence

Retrovirology

Ben Berkhout¹  Vladimir V Lukashov¹  Alexander O Pasternak¹ 

[1]Department of Medical Microbiology, Laboratory of Experimental Virology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Meibergdreef 15, Amsterdam, 1105 AZ, The Netherlands

关键词: HIV cure;    Antiretroviral therapy;    HIV-1 reservoir;    HIV-1 persistence;    Virological biomarker;    Cell-associated HIV RNA;   

Others  :  1209138
DOI  :  10.1186/1742-4690-10-41

 received in 2013-02-12, accepted in 2013-04-10,  发布年份 2013

【 摘 要 】

In most HIV-infected individuals adherent to modern antiretroviral therapy (ART), plasma viremia stays undetectable by clinical assays and therefore, additional virological markers for monitoring and predicting therapy responses and for measuring the degree of HIV persistence in patients on ART should be identified. For the above purposes, quantitation of cell-associated HIV biomarkers could provide a useful alternative to measurements of viral RNA in plasma. This review concentrates on cell-associated (CA) HIV RNA with the emphasis on its use as a virological biomarker. We discuss the significance of CA HIV RNA as a prognostic marker of disease progression in untreated patients and as an indicator of residual virus replication and the size of the dynamic viral reservoir in ART-treated patients. Potential value of this biomarker for monitoring the response to ART and to novel HIV eradication therapies is highlighted.

【 授权许可】

   
2013 Pasternak et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
• [2]Siliciano JD, Siliciano RF: Biomarkers of HIV replication. Curr Opin HIV AIDS 2010, 5:491-497.
• [3]Doyle T, Geretti AM: Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis 2012, 25:17-25.
• [4]Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Mascio MD, Katlama C: Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12:607-614.
• [5]Lewin SR, Rouzioux C: HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011, 25:885-897.
• [6]Lafeuillade A: Eliminating the HIV reservoir. Curr HIV/AIDS Rep 2012, 9:121-131.
• [7]Smith MZ, Wightman F, Lewin SR: HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 2012, 9:5-15.
• [8]Hilldorfer BB, Cillo AR, Besson GJ, Bedison MA, Mellors JW: New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr HIV/AIDS Rep 2012, 9:91-100.
• [9]Avettand-Fenoel V, Chaix ML, Blanche S, Burgard M, Floch C, Toure K, Allemon MC, Warszawski J, Rouzioux C: LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009, 81:217-223.
• [10]Pace MJ, Agosto L, Graf EH, O'Doherty U: HIV reservoirs and latency models. Virology 2011, 411:344-354.
• [11]Sloan RD, Wainberg MA: The role of unintegrated DNA in HIV infection. Retrovirology 2011, 8:52. BioMed Central Full Text
• [12]Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
• [13]Schwartz S, Felber BK, Benko DM, Fenyo EM, Pavlakis GN: Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol 1990, 64:2519-2529.
• [14]Purcell DF, Martin MA: Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 1993, 67:6365-6378.
• [15]Kim SY, Byrn R, Groopman J, Baltimore D: Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989, 63:3708-3713.
• [16]Cullen BR, Greene WC: Regulatory pathways governing HIV-1 replication. Cell 1989, 58:423-426.
• [17]Karn J, Stoltzfus CM: Transcriptional and Posttranscriptional Regulation of HIV-1 Gene Expression. Cold Spring Harb Perspect Med 2012, 2:a006916.
• [18]Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR: The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989, 338:254-257.
• [19]Malim MH, Cullen BR: HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency. Cell 1991, 65:241-248.
• [20]Exline CM, Feng Z, Stoltzfus CM: Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 vif gene expression. J Virol 2008, 82:3921-3931.
• [21]Pollard VW, Malim MH: The HIV-1 Rev protein. Annu Rev Microbiol 1998, 52:491-532.
• [22]Schnittman SM, Greenhouse JJ, Lane HC, Pierce PF, Fauci AS: Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. AIDS Res Hum Retroviruses 1991, 7:361-367.
• [23]Michael NL, Vahey M, Burke DS, Redfield RR: Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol 1992, 66:310-316.
• [24]Seshamma T, Bagasra O, Trono D, Baltimore D, Pomerantz RJ: Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992, 89:10663-10667.
• [25]Bagnarelli P, Menzo S, Valenza A, Manzin A, Giacca M, Ancarani F, Scalise G, Varaldo PE, Clementi M: Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 1992, 66:7328-7335.
• [26]Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, Fauci AS: Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci U S A 1993, 90:6405-6409.
• [27]Furtado MR, Murphy R, Wolinsky SM: Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy. J Infect Dis 1993, 167:213-216.
• [28]Gupta P, Kingsley L, Armstrong J, Ding M, Cottrill M, Rinaldo C: Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology 1993, 196:586-595.
• [29]Patterson BK, Till M, Otto P, Goolsby C, Furtado MR, McBride LJ, Wolinsky SM: Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science 1993, 260:976-979.
• [30]Arens M, Joseph T, Nag S, Miller JP, Powderly WG, Ratner L: Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. AIDS Res Hum Retroviruses 1993, 9:1257-1263.
• [31]Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362:359-362.
• [32]Embretson J, Zupancic M, Beneke J, Till M, Wolinsky S, Ribas JL, Burke A, Haase AT: Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc Natl Acad Sci U S A 1993, 90:357-361.
• [33]Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362:355-358.
• [34]Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang ZQ: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996, 274:985-989.
• [35]Brachtel EF, Mascola JR, Wear DJ, Ehrenberg PK, Dayhoff DE, Sanders-Buell E, Michael NL, Frankel SS: Demonstration of de novo HIV type 1 production by detection of multiply spliced and unspliced HIV type 1 RNA in paraffin-embedded tonsils. AIDS Res Hum Retroviruses 2002, 18:785-790.
• [36]Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D: HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995, 123:641-648.
• [37]Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
• [38]Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
• [39]Henrard DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, Goedert JJ: Natural history of HIV-1 cell-free viremia. JAMA 1995, 274:554-558.
• [40]de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, Roos M, Coutinho R, Miedema F, Goudsmit J: AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997, 11:1799-1806.
• [41]Sabin CA, Devereux H, Phillips AN, Hill A, Janossy G, Lee CA, Loveday C: Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 2000, 23:172-177.
• [42]Furtado MR, Kingsley LA, Wolinsky SM: Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol 1995, 69:2092-2100.
• [43]Saltarelli MJ, Hadziyannis E, Hart CE, Harrison JV, Felber BK, Spira TJ, Pavlakis GN: Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. AIDS Res Hum Retroviruses 1996, 12:1443-1456.
• [44]Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV: Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia. AIDS 2010, 24:1641-1649.
• [45]Saksela K, Stevens C, Rubinstein P, Baltimore D: Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc Natl Acad Sci U S A 1994, 91:1104-1108.
• [46]Michael NL, Mo T, Merzouki A, O'Shaughnessy M, Oster C, Burke DS, Redfield RR, Birx DL, Cassol SA: Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 1995, 69:1868-1877.
• [47]Comar M, Simonelli C, Zanussi S, Paoli P, Vaccher E, Tirelli U, Giacca M: Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest 1997, 100:893-903.
• [48]Pomerantz RJ, Trono D, Feinberg MB, Baltimore D: Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell 1990, 61:1271-1276.
• [49]Michael NL, Morrow P, Mosca J, Vahey M, Burke DS, Redfield RR: Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol 1991, 65:7084.
• [50]Huynen MA, Neumann AU: Rate of killing of HIV-infected T cells and disease progression. Science 1996, 272:1962.
• [51]Wolinsky SM, Korber BT, Neumann AU, Daniels M, Kunstman KJ, Whetsell AJ, Furtado MR, Cao Y, Ho DD, Safrit JT: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996, 272:537-542.
• [52]Wong JK, Gunthard HF, Havlir DV, Zhang ZQ, Haase AT, Ignacio CC, Kwok S, Emini E, Richman DD: Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A 1997, 94:12574-12579.
• [53]Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, Richman DD: Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998, 72:2422-2428.
• [54]Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Jin X, Chaudhry MR, Yaman M: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999, 179:527-537.
• [55]Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, Perrin L: Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study. J Infect Dis 1999, 180:850-853.
• [56]Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA: HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 1999, 353:119-120.
• [57]Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM, Bucy RP: Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 1999, 189:1545-1554.
• [58]Lewin SR, Vesanen M, Kostrikis L, Hurley A, Duran M, Zhang L, Ho DD, Markowitz M: Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol 1999, 73:6099-6103.
• [59]Fischer M, Gunthard HF, Opravil M, Joos B, Huber W, Bisset LR, Ott P, Boni J, Weber R, Cone RW: Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 2000, 16:1135-1140.
• [60]Gunthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W: Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001, 183:1318-1327.
• [61]Patterson BK, McCallister S, Schutz M, Siegel JN, Shults K, Flener Z, Landay A: Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS 2001, 15:1635-1641.
• [62]Zhang J, Crumpacker CS: Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy. J Infect Dis 2001, 184:1341-1344.
• [63]Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, Hwangbo Y, Mullins JI, Corey L: Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002, 76:707-716.
• [64]Chun TW, Justement JS, Lempicki RA, Yang J, Dennis G Jr, Hallahan CW, Sanford C, Pandya P, Liu S, McLaughlin M: Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci U S A 2003, 100:1908-1913.
• [65]Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Gunthard HF: Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef. J Infect Dis 2004, 190:1979-1988.
• [66]Zanchetta M, Walker S, Burighel N, Bellanova D, Rampon O, Giaquinto C, De Rossi A: Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J Infect Dis 2006, 193:1718-1727.
• [67]Kaiser P, Joos B, Niederost B, Weber R, Gunthard HF, Fischer M: Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol 2007, 81:9693-9706.
• [68]Soares RS, Matoso P, Calado M, Sousa AE: Strategies to quantify unspliced and multiply spliced mRNA expression in HIV-2 infection. J Virol Methods 2011, 175:38-45.
• [69]Pasternak AO, Adema KW, Bakker M, Jurriaans S, Berkhout B, Cornelissen M, Lukashov VV: Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol 2008, 46:2206-2211.
• [70]Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV: Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 2009, 4:e8490.
• [71]Fischer M, Huber W, Kallivroussis A, Ott P, Opravil M, Luthy R, Weber R, Cone RW: Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J Clin Microbiol 1999, 37:1260-1264.
• [72]Kupfer B, Matz B, Daumer MP, Roden F, Rockstroh JK, Qurishi N, Spengler U, Kaiser R: Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml. J Med Virol 2007, 79:1440-1445.
• [73]Patterson BK, Carlo DJ, Kaplan MH, Marecki M, Pawha S, Moss RB: Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS 1999, 13:1607-1611.
• [74]Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM: A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011, 203:960-968.
• [75]Kuchipudi SV, Tellabati M, Nelli RK, White GA, Perez BB, Sebastian S, Slomka MJ, Brookes SM, Brown IH, Dunham SP: 18S rRNA is a reliable normalisation gene for real time PCR based on influenza virus infected cells. Virol J 2012, 9:230. BioMed Central Full Text
• [76]Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh TA, Anderson J, Post F, Pillay D, Gazzard B, Hill T: Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? J Infect Dis 2012, 205:540-547.
• [77]Kwok S, Kellogg DE, McKinney N, Spasic D, Goda L, Levenson C, Sninsky JJ: Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 1990, 18:999-1005.
• [78]Bru D, Martin-Laurent F, Philippot L: Quantification of the detrimental effect of a single primer-template mismatch by real-time PCR using the 16S rRNA gene as an example. Appl Environ Microbiol 2008, 74:1660-1663.
• [79]Suss B, Flekna G, Wagner M, Hein I: Studying the effect of single mismatches in primer and probe binding regions on amplification curves and quantification in real-time PCR. J Microbiol Methods 2009, 76:316-319.
• [80]Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, Taylor N, Eberle J: Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 2009, 47:1238-1240.
• [81]Desire N, Dehee A, Schneider V, Jacomet C, Goujon C, Girard PM, Rozenbaum W, Nicolas JC: Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol 2001, 39:1303-1310.
• [82]Kondo M, Sudo K, Tanaka R, Sano T, Sagara H, Iwamuro S, Takebe Y, Imai M, Kato S: Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR. J Virol Methods 2009, 157:141-146.
• [83]Rozera G, Abbate I, Bruselles A, Bartolini B, D'Offizi G, Nicastri E, Tommasi C, Capobianchi MR: Comparison of real-time PCR methods for measurement of HIV-1 proviral DNA. J Virol Methods 2010, 164:135-138.
• [84]van der Sluis RM, van Montfort T, Centlivre M, Schopman NC, Cornelissen M, Sanders RW, Berkhout B, Jeeninga RE, Paxton WA, Pollakis G: Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity. J Virol Methods 2013, 187:94-102.
• [85]Schmid A, Gianella S, von Wyl V, Metzner KJ, Scherrer AU, Niederost B, Althaus CF, Rieder P, Grube C, Joos B: Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One 2010, 5:e13310.
• [86]Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA: New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003, 41:4531-4536.
• [87]Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627-1632.
• [88]Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, Pomerantz RJ, Perelson AS: In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol 2003, 77:2271-2275.
• [89]Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S: Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005, 19:1843-1847.
• [90]Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Gunthard HF: Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001, 286:171-179.
• [91]Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, Furrer H, Hirschel B, Perrin L: Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS 2000, 14:243-249.
• [92]Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R: ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007, 3:e46.
• [93]Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS: Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008, 105:3879-3884.
• [94]Bagnarelli P, Valenza A, Menzo S, Sampaolesi R, Varaldo PE, Butini L, Montroni M, Perno CF, Aquaro S, Mathez D: Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol 1996, 70:7603-7613.
• [95]Burgisser P, Spertini F, Weyrich-Suter C, Pagani JL, Meylan PR: Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration. J Infect Dis 1997, 175:1202-1205.
• [96]Garrigue I, Pellegrin I, Hoen B, Dumon B, Harzic M, Schrive MH, Sereni D, Fleury H: Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS 2000, 14:2851-2855.
• [97]Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L: Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000, 14:2805-2812.
• [98]Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B: Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007, 45:381-390.
• [99]Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
• [100]Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD: Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354:1782-1785.
• [101]Finzi D, Siliciano RF: Viral dynamics in HIV-1 infection. Cell 1998, 93:665-671.
• [102]Wodarz D, Nowak MA: Mathematical models of HIV pathogenesis and treatment. Bioessays 2002, 24:1178-1187.
• [103]Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF: Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog 2006, 2:e68.
• [104]Dandri M, Murray JM, Lutgehetmann M, Volz T, Lohse AW, Petersen J: Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia. Hepatology 2008, 48:1079-1086.
• [105]Zhang L, Dailey PJ, He T, Gettie A, Bonhoeffer S, Perelson AS, Ho DD: Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J Virol 1999, 73:855-860.
• [106]Igarashi T, Brown C, Azadegan A, Haigwood N, Dimitrov D, Martin MA, Shibata R: Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat Med 1999, 5:211-216.
• [107]Morris MK, Katzenstein DA, Israelski D, Zolopa A, Hendry RM, Hanson CV: Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2001, 28:405-415.
• [108]Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF: Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006, 80:4758-4770.
• [109]Fischer M, Wong JK, Russenberger D, Joos B, Opravil M, Hirschel B, Trkola A, Kuster H, Weber R, Gunthard HF: Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antivir Ther 2002, 7:91-103.
• [110]Fischer M, Trkola A, Joos B, Hafner R, Joller H, Muesing MA, Kaufman DR, Berli E, Hirschel B, Weber R: Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antivir Ther 2003, 8:97-104.
• [111]Fischer M, Joos B, Wong JK, Ott P, Opravil M, Hirschel B, Weber R, Gunthard HF: Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy. J Infect Dis 2004, 189:273-285.
• [112]Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, von Wyl V, Ackermann M, Weber R, Gunthard HF: Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 2008, 5:107. BioMed Central Full Text
• [113]Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003, 9:727-728.
• [114]Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, Quinn TC, Siliciano RF: Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 2003, 77:7383-7392.
• [115]Lassen KG, Bailey JR, Siliciano RF: Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol 2004, 78:9105-9114.
• [116]Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G, Pereira C, Purcell D, Cameron PU, Lewin SR: Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology 2011, 8:80. BioMed Central Full Text
• [117]Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ: HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005, 115:3250-3255.
• [118]Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, Brady T, Bushman FD, O'Doherty U: Directly Infected Resting CD4+T Cells Can Produce HIV Gag without Spreading Infection in a Model of HIV Latency. PLoS Pathog 2012, 8:e1002818.
• [119]Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G: Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients. PLoS One 2012, 7:e37792.
• [120]Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di MM, Migueles SA, Connors M, O'Doherty U: Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 2011, 7:e1001300.
• [121]Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF: Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007, 81:2508-2518.
• [122]Strain MC, Little SJ, Daar ES, Havlir DV, Gunthard HF, Lam RY, Daly OA, Nguyen J, Ignacio CC, Spina CA: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005, 191:1410-1418.
• [123]Deeks SG: HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011, 62:141-155.
• [124]van Sighem A, Danner S, Ghani AC, Gras L, Anderson RM, de Wolf F: Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals. J Acquir Immune Defic Syndr 2005, 40:212-218.
• [125]Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, Vaeth M, Obel N: Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007, 146:87-95.
• [126]The Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299.
• [127]Soares RS, Tendeiro R, Foxall RB, Baptista AP, Cavaleiro R, Gomes P, Camacho R, Valadas E, Doroana M, Lucas M: Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol 2011, 85:2429-2438.
• [128]Hunt PW, Hatano H, Sinclair E, Lee TH, Busch MP, Martin JN, McCune JM, Deeks SG: HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers. Clin Infect Dis 2011, 52:681-687.
• [129]Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F: Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T cells. J Infect Dis 2012. [Epub ahead of print]
• [130]Shen L, Siliciano RF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 2008, 122:22-28.
• [131]Maldarelli F: Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication. Curr Opin HIV AIDS 2011, 6:49-56.
• [132]Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, Hirschel B, Weber R, Trkola A, Gunthard HF: HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci U S A 2008, 105:16725-16730.
• [133]Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD: The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000, 6:82-85.
• [134]Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
• [135]Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, Holte SE, De Vange SM, Pawluk DM, Melvin AJ: Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 2003, 77:5721-5730.
• [136]Deeks SG: HIV: How to escape treatment. Nature 2011, 477:36-37.
• [137]Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J: Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006, 80:6441-6457.
• [138]Evering TH, Mehandru S, Racz P, Tenner-Racz K, Poles MA, Figueroa A, Mohri H, Markowitz M: Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012, 8:e1002506.
• [139]Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D: HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 2001, 286:196-207.
• [140]Josefsson L, Faria N, Eriksson S, Sinclair E, Shao W, Hunt P, Somsouk M, Deeks SG, Hecht F, Palmer S: In-depth Phylogenetic Analyses of HIV-1 Evolution during Long-term Suppressive Therapy [abstract]. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Georgia; 2013.
• [141]Vesanen M, Markowitz M, Cao Y, Ho DD, Saksela K: Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Virology 1997, 236:104-109.
• [142]Josefsson L, Eriksson S, Sinclair E, Ho T, Killian M, Epling L, Shao W, Lewis B, Hunt P, Somsouk M: Characterizing Latent HIV Reservoirs [abstract]. Global Antiviral Journal 2011, 7(Suppl 2):11-12.
• [143]Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Gunthard HF, Fischer M: Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010, 24:2451-2460.
• [144]Shults K, Flye-Blakemore L, Patterson BK, Elbeik T: Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy. Future Virol 2012, 7:819-832.
• [145]Pasternak AO, de Bruin M, Jurriaans S, Bakker M, Berkhout B, Prins JM, Lukashov VV: Modest Nonadherence to Antiretroviral Therapy Promotes Residual HIV-1 Replication in the Absence of Virological Rebound in Plasma. J Infect Dis 2012, 206:1443-1452.
• [146]Shuter J: Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008, 61:769-773.
• [147]Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B: Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293:817-829.
• [148]Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D: Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011, 477:95-98.
• [149]Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI: Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008, 197:714-720.
• [150]Lafeuillade A, Cheret A, Hittinger G, Bernardini D, Cuquemelle C, Jullian E, Poggi C: Rectal cell-associated HIV-1 RNA: a new marker ready for the clinic. HIV Clin Trials 2009, 10:324-327.
• [151]North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA: Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010, 84:2913-2922.
• [152]Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T, Li P: Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010, 202:1553-1561.
• [153]Horiike M, Iwami S, Kodama M, Sato A, Watanabe Y, Yasui M, Ishida Y, Kobayashi T, Miura T, Igarashi T: Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology 2012, 423:107-118.
• [154]Cohen J: HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 2011, 334:1614.
• [155]Imamichi H, Degray G, Dewar RL, Mannon P, Yao M, Chairez C, Sereti I, Kovacs JA: Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. J Infect Dis 2011, 204:309-314.
• [156]McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C: Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010, 50:912-919.
• [157]Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM: The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010, 7:e1000321.
• [158]Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010, 16:460-465.
• [159]Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C: Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000, 6:76-81.
• [160]Sharkey M, Triques K, Kuritzkes DR, Stevenson M: In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol 2005, 79:5203-5210.
• [161]Butler SL, Johnson EP, Bushman FD: Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002, 76:3739-3747.
• [162]Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF: Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002, 76:4138-4144.
• [163]Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M: Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther 2012, 17:355-364.
• [164]Besson GJ, McMahon D, Maldarelli F, Mellors JW: Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clin Infect Dis 2012, 54:451-453.
• [165]Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA: No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012, 59:229-235.
• [166]Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M: Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog 2011, 7:e1001303.
• [167]Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012, 487:482-485.